A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.

IF 10.8 1区医学 Q1 NEUROSCIENCES

Translational Neurodegeneration Pub Date : 2023-11-16 DOI:10.1186/s40035-023-00387-5

Alireza Faridar, Abdulmunaim M Eid, Aaron D Thome, Weihua Zhao, David R Beers, Maria B Pascual, Mohammad O Nakawah, Gustavo C Roman, Charles S Davis, Michael Grundman, Joseph C Masdeu, Stanley H Appel

引用次数: 0

Abstract

Trial registration: ClinicalTrials.gov Identifier: NCT05821153, Registered April 20 2023, Retrospectively registered, https://classic.

Clinicaltrials: gov/ct2/show/NCT05821153.

查看原文本刊更多论文

低剂量白介素-2免疫治疗阿尔茨海默病患者的1期开放标签试点研究

试验注册:ClinicalTrials.gov标识符:NCT05821153，注册于2023年4月20日，回顾性注册，https://classic.Clinicaltrials: gov/ct2/show/NCT05821153。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational Neurodegeneration Neuroscience-Cognitive Neuroscience

CiteScore

19.50

自引率

0.80%

发文量

审稿时长

10 weeks

期刊介绍： Translational Neurodegeneration, an open-access, peer-reviewed journal, addresses all aspects of neurodegenerative diseases. It serves as a prominent platform for research, therapeutics, and education, fostering discussions and insights across basic, translational, and clinical research domains. Covering Parkinson's disease, Alzheimer's disease, and other neurodegenerative conditions, it welcomes contributions on epidemiology, pathogenesis, diagnosis, prevention, drug development, rehabilitation, and drug delivery. Scientists, clinicians, and physician-scientists are encouraged to share their work in this specialized journal tailored to their fields.